Commercialization of ultrasensitive methods for analysis of circulating tumor DNA in cancer patients
| Reference number | |
| Coordinator | SAGA DIAGNOSTICS AB |
| Funding from Vinnova | SEK 4 700 000 |
| Project duration | November 2018 - October 2020 |
| Status | Completed |
Important results from the project
In this SWElife step 2 project SAGA has successfully managed to develop and implement a marketing and sales strategy including the employment of our first salespeople. We established our commercial laboratory and gained significant traction delivering services to research centres and biopharma customers with unique SAGA technology. ISO accreditation has been applied for and is expected shortly. With our first CE-IVD-marked product we enter the healthcare market. Successful verification of SAGAsafe and prototyping of SAGAseq shows great promise.
Expected long term effects
The results of this project have had a significant impact on SAGA. SAGA has an excellent understanding of the market and competition. With the commercial laboratory, we already have significant traction. With our first CE-IVD marking as a template, we now have a pipeline of CE-IVD SAGAsafe kits for 2021. SWElife support has allowed us to increase our knowledge and competence and perform important technical verification work. This progress has made SAGA attractive towards larger European investors for the next phase of company growth.
Approach and implementation
We have completed almost all of our aims in the three work packages, which included activities in business development, regulatory affairs, and technical verification. We completed most of our milestones on schedule. We had to deviate from the plan, primarily in work package 3, primarily related to the covid-19 pandemic and subsequent delays in the onboarding of two scientists from abroad.